117 related articles for article (PubMed ID: 28991465)
41. CBL mutation-related patterns of phosphorylation and sensitivity to tyrosine kinase inhibitors.
Makishima H; Sugimoto Y; Szpurka H; Clemente MJ; Ng KP; Muramatsu H; O'Keefe C; Saunthararajah Y; Maciejewski JP
Leukemia; 2012 Jul; 26(7):1547-54. PubMed ID: 22246246
[TBL] [Abstract][Full Text] [Related]
42. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
Ali MA
Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
[TBL] [Abstract][Full Text] [Related]
43. Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
Halbach S; Hu Z; Gretzmeier C; Ellermann J; Wöhrle FU; Dengjel J; Brummer T
Cell Commun Signal; 2016 Feb; 14():6. PubMed ID: 26912052
[TBL] [Abstract][Full Text] [Related]
44. A shift of dynamic equilibrium between the KIT active and inactive states causes drug resistance.
Srikakulam SK; Bastys T; Kalinina OV
Proteins; 2020 Nov; 88(11):1434-1446. PubMed ID: 32530065
[TBL] [Abstract][Full Text] [Related]
45. Gastrointestinal stromal tumors: overview of pathologic features, molecular biology, and therapy with imatinib mesylate.
Koh JS; Trent J; Chen L; El-Naggar A; Hunt K; Pollock R; Zhang W
Histol Histopathol; 2004 Apr; 19(2):565-74. PubMed ID: 15024716
[TBL] [Abstract][Full Text] [Related]
46. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.
Ernst T; Erben P; Müller MC; Paschka P; Schenk T; Hoffmann J; Kreil S; La Rosée P; Hehlmann R; Hochhaus A
Haematologica; 2008 Feb; 93(2):186-92. PubMed ID: 18223278
[TBL] [Abstract][Full Text] [Related]
47. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
48. KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors.
Lai S; Wang G; Cao X; Luo X; Wang G; Xia X; Hu J; Wang J
Oncotarget; 2016 Jan; 7(2):1367-79. PubMed ID: 26587973
[TBL] [Abstract][Full Text] [Related]
49. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.
O'Hare T; Walters DK; Stoffregen EP; Sherbenou DW; Heinrich MC; Deininger MW; Druker BJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6987-93. PubMed ID: 16203792
[TBL] [Abstract][Full Text] [Related]
50. [The diagnostic and predictive role of kit (CD117)].
Dirnhofer S; Zimpfer A; Went P
Ther Umsch; 2006 Apr; 63(4):273-8. PubMed ID: 16689459
[TBL] [Abstract][Full Text] [Related]
51. Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.
Serrano C; George S; Valverde C; Olivares D; García-Valverde A; Suárez C; Morales-Barrera R; Carles J
Target Oncol; 2017 Jun; 12(3):277-288. PubMed ID: 28478525
[TBL] [Abstract][Full Text] [Related]
52. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
53. Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells.
Abbaspour Babaei M; Kamalidehghan B; Saleem M; Huri HZ; Ahmadipour F
Drug Des Devel Ther; 2016; 10():2443-59. PubMed ID: 27536065
[TBL] [Abstract][Full Text] [Related]
54. Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.
Deininger MW
J Cancer Res Clin Oncol; 2004 Feb; 130(2):59-72. PubMed ID: 14605878
[TBL] [Abstract][Full Text] [Related]
55. Dual Drug Targeting of Mutant Bcr-Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance.
El Rashedy AA; Olotu FA; Soliman MES
Chem Biodivers; 2018 Mar; 15(3):e1700533. PubMed ID: 29325229
[TBL] [Abstract][Full Text] [Related]
56. ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT.
Apsel Winger B; Cortopassi WA; Garrido Ruiz D; Ding L; Jang K; Leyte-Vidal A; Zhang N; Esteve-Puig R; Jacobson MP; Shah NP
Cancer Res; 2019 Aug; 79(16):4283-4292. PubMed ID: 31270078
[TBL] [Abstract][Full Text] [Related]
57. Distinct cellular properties of oncogenic KIT receptor tyrosine kinase mutants enable alternative courses of cancer cell inhibition.
Shi X; Sousa LP; Mandel-Bausch EM; Tome F; Reshetnyak AV; Hadari Y; Schlessinger J; Lax I
Proc Natl Acad Sci U S A; 2016 Aug; 113(33):E4784-93. PubMed ID: 27482095
[TBL] [Abstract][Full Text] [Related]
58. Design of antitumor drugs targeting c-kit receptor by a new mixed ligand-structure based method.
Martorana A; Lauria A
J Mol Graph Model; 2020 Nov; 100():107666. PubMed ID: 32659630
[TBL] [Abstract][Full Text] [Related]
59. Identification of novel
Elasbali AM; Al-Soud WA; Elfaki EM; Alanazi HH; Alharbi B; Alharethi SH; Anwer K; Mohammad T; Hassan MI
J Biomol Struct Dyn; 2024 Jul; 42(11):5982-5994. PubMed ID: 37403288
[TBL] [Abstract][Full Text] [Related]
60. Developing and Characterization of Chemically Modified RNA Aptamers for Targeting Wild Type and Mutated c-KIT Receptor Tyrosine Kinases.
Shraim AS; Hunaiti A; Awidi A; Alshaer W; Ababneh NA; Abu-Irmaileh B; Odeh F; Ismail S
J Med Chem; 2020 Mar; 63(5):2209-2228. PubMed ID: 31369705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
